/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology ( I&I ) markets, including for the treatment of atopic dermatitis ( AD ), asthma, eosinophilic esophagitis ( EoE ), chronic obstructive pulmonary disease ( COPD ), and other I&I indications. Our antibody …
$135.07
+$0.00 (+0.00%)
Price from 17 days ago
Negative free cash flow of -$233M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$294M
▼ -40.5% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$244M
▼ -35.0% YoY
Op. Cash Flow (TTM)
-$244M
▼ -32.9% YoY
Net Debt
-$965M
Net Cash Position
Cash & Equiv.
$972M
Continue Research
SourceComputed from the 10-Q filed 10 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.
Price from market data, last close as of 3 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.